Terms: = Kidney tumors AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Treatment
16 results:
1. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Kato T; Nakano Y; Hongo F; Katano H; Miyagawa T; Ueda K; Azuma H; Nozawa M; Hinata N; Hori J; Otoshi T; Shimizu N; Aizawa M; Osada S; Matsui A; Oya M; Eto M; Tomita Y; Shinohara N; Uemura H
Int J Urol; 2024 Mar; 31(3):265-272. PubMed ID: 38110838
[TBL] [Abstract] [Full Text] [Related]
2. Cost-effectiveness of nivolumab and ipilimumab versus pembrolizumab and axitinib in advanced renal cell carcinoma with intermediate or poor prognostic risk: a Brazilian private healthcare system perspective.
Dhanji N; Decimoni TC; Dyer MTD; May JR; van de Wetering G; Petersohn S; Nickel K; Silva A; Muniz DQB; Casagrande D Oliveira AP
J Med Econ; 2023; 26(1):1108-1121. PubMed ID: 37632452
[TBL] [Abstract] [Full Text] [Related]
3. Health-Related Quality of Life Outcomes With Two Different Starting Doses of Lenvatinib in Combination With Everolimus for Previously Treated Renal Cell Carcinoma.
Bergerot C; Young Rha S; Pal S; Koralewski P; Stroyakovskiy D; Alekseev B; Parnis F; Castellano D; Lyun Lee J; Sunela K; Ciuleanu T; Heng D; Glen H; Wang J; Bennett L; Pan J; O'Hara K; Puente J
Oncologist; 2023 Jan; 28(1):59-71. PubMed ID: 35881028
[TBL] [Abstract] [Full Text] [Related]
4. Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy.
Bhanegaonkar A; Pandya S; Zheng Y; Kim R; Krulewicz S; Kasturi V; Phatak H
Adv Ther; 2021 May; 38(5):2644-2661. PubMed ID: 33866526
[TBL] [Abstract] [Full Text] [Related]
5. Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway.
Liu H; Li X; Duan Y; Xie JB; Piao XL
J Ethnopharmacol; 2021 May; 271():113907. PubMed ID: 33556477
[TBL] [Abstract] [Full Text] [Related]
6. Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity.
Hermansen CK; Donskov F
J Geriatr Oncol; 2021 Jun; 12(5):827-833. PubMed ID: 33388280
[TBL] [Abstract] [Full Text] [Related]
7. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab
Atkins MB; Rini BI; Motzer RJ; Powles T; McDermott DF; Suarez C; Bracarda S; Stadler WM; Donskov F; Gurney H; Oudard S; Uemura M; Lam ET; Grüllich C; Quach C; Carroll S; Ding B; Zhu QC; Piault-Louis E; Schiff C; Escudier B
Clin Cancer Res; 2020 Jun; 26(11):2506-2514. PubMed ID: 32127394
[TBL] [Abstract] [Full Text] [Related]
8. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
[TBL] [Abstract] [Full Text] [Related]
9. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
Graham J; Shah AY; Wells JC; McKay RR; Vaishampayan U; Hansen A; Donskov F; Bjarnason GA; Beuselinck B; De Velasco G; Iafolla M; Duh MS; Huynh L; Chang R; Zanotti G; Ramaswamy K; Choueiri TK; Tannir NM; Heng DYC
Eur Urol Oncol; 2021 Feb; 4(1):102-111. PubMed ID: 31786162
[TBL] [Abstract] [Full Text] [Related]
10. Evolving Role of Genomics in Genitourinary Neoplasms.
Devitt ME; Dreicer R
Acta Med Acad; 2019 Apr; 48(1):68-77. PubMed ID: 31264434
[TBL] [Abstract] [Full Text] [Related]
11. [Efficacy of albumin-bound paclitaxel in advanced gastric cancer patients].
Gong JF; Lu M; Li J; Li Y; Zhou J; Lu ZH; Wang XC; Li J; Zhang XT; Shen L
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Feb; 46(1):144-8. PubMed ID: 24535367
[TBL] [Abstract] [Full Text] [Related]
12. Trends in renal function after radical nephrectomy: a multicentre analysis.
Chung JS; Son NH; Byun SS; Lee SE; Hong SK; Jeong CW; Lee SC; Chae DW; Choi WS; Park YH; Hong SH; Kim YJ; Kang SH
BJU Int; 2014 Mar; 113(3):408-15. PubMed ID: 23937424
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial.
Porta C; Calvo E; Climent MA; Vaishampayan U; Osanto S; Ravaud A; Bracarda S; Hutson TE; Escudier B; Grünwald V; Kim D; Panneerselvam A; Anak O; Motzer RJ
Eur Urol; 2012 Apr; 61(4):826-33. PubMed ID: 22297244
[TBL] [Abstract] [Full Text] [Related]
14. Analysis of skin cancer risk factors in immunosuppressed renal transplant patients shows high levels of UV-specific tandem CC to TT mutations of the p53 gene.
Queille S; Luron L; Spatz A; Avril MF; Ribrag V; Duvillard P; Hiesse C; Sarasin A; Armand JP; Daya-Grosjean L
Carcinogenesis; 2007 Mar; 28(3):724-31. PubMed ID: 17065198
[TBL] [Abstract] [Full Text] [Related]
15. Therapy and prognosis of tumors of the genitourinary tract after kidney transplantation.
Diller R; Gruber A; Wolters H; Senninger N; Spiegel HU
Transplant Proc; 2005 Jun; 37(5):2089-92. PubMed ID: 15964347
[TBL] [Abstract] [Full Text] [Related]
16. Thoracoscopy and transplantation: a new attractive tool.
Roviaro G; Varoli F; Francese M; Caminiti R; Vergani C; Maciocco M
Transplantation; 2002 Apr; 73(7):1013-8. PubMed ID: 11965025
[TBL] [Abstract] [Full Text] [Related]
